ReviewClinical medicine (London, England)2017
Developments in therapy with monoclonal antibodies and related proteins.
Review in Clinical medicine (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed.
- Real-world use of monoclonal anti-tetanus toxin antibody for post-traumatic passive immunization: A nationwide survey in China.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2026Observational
- Pipettes and Pipelines: The Weapons of Omics Sciences for a New Age of Clinical Studies.Current issues in molecular biology · 2026Review
- Women's Special Issue Series: Biomedicines (2nd Edition).Biomedicines · 2026Article
- Experimental models in immuno-oncology and their translational impact.Discover oncology · 2026Review
- Prediction of Human Serum Concentration-Time Profiles of Golimumab and Ustekinumab Using Pharmacokinetic Data From Common Marmosets With Assessment of Anti-Drug Antibodies.Biopharmaceutics & drug disposition · 2026Article
- Pharmacokinetics of Monoclonal Antibodies in Pediatrics: Model-Based Investigation on Allometric Scaling Exponents.Pharmaceutics · 2026Article
- Progress in cell-based immunotherapies for solid tumors.Discover oncology · 2026Review
- Enhanced cleaning strategies for UF/DF membranes in biopharmaceutical downstream processing.Bioresources and bioprocessing · 2026Article
- Precise Control of Drug Release in Machine Learning-Designed Antibody-Eluting Implants for Postoperative Scarring Inhibition in Glaucoma.Advanced healthcare materials · 2026Article
- Transplacental Antibody Transfer: Mechanisms, Pregnancy-Related Disruptions, and Emerging Experimental Models.Antibodies (Basel, Switzerland) · 2026Review
- Antibody Screening and Binding Prediction Analysis Targeting Stx2.Antibodies (Basel, Switzerland) · 2026Article
- Developing affordable monoclonal antibodies for LMICs through high performance manufacturing processes and LMIC based commercial manufacturing.Frontiers in pediatrics · 2026Article
- Cancer Immunotherapies: Navigating the Immune Landscape.Current cancer drug targets · 2026Review
- Infection-sensing minigenome as a novel therapeutic approach against Ebola virus.Molecular therapy. Nucleic acids · 2025Article
- CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy.bioRxiv : the preprint server for biology · 2025Article
- Article
- Research progress on TMEM proteins in cancer progression and chemoresistance (Review).International journal of molecular medicine · 2025Review
- Cure of experimentalmBio · 2025Article
- Mendelian randomization study implicates inflammaging biomarkers in retinal vasculature, cardiovascular diseases, and longevity.Science advances · 2025Article
- Characteristics of patients who developed transient anti-adalimumab antibodies.Journal of ophthalmic inflammation and infection · 2025Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibody therapeutics have been approved for over 30 targets and diseases, most commonly cancer. Antibodies have become the new backbone of the pharmaceutical industry, which previously relied on small molecules. Compared with small molecules, monoclonal antibodies (mAbs) have exquisite target selectivity and hence less toxicity as a result of binding other targets. The clinical value of both mAbs and ligand traps has been proven. New applications of mAbs are being tested and mAbs have now been designed to target two (bi-specific, eg TNF-α and IL-17) or more targets simultaneously, augmenting their therapeutic potential. Because of space limitations and the wide ranging scope of this review there are regrettably, but inevitably, omissions and missing citations. We have chosen to highlight the first successes in inflammatory diseases and cancer, but a broader overview of approved mAbs and related molecules can be found in Table 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.